🇺🇸 FDA
Pipeline program

KT-413

KT413-DL-101

Phase 1 small_molecule completed

Quick answer

KT-413 for Non Hodgkin Lymphoma is a Phase 1 program (small_molecule) at Kymera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Kymera Therapeutics
Indication
Non Hodgkin Lymphoma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials